Which option describes CGRP antagonists used for migraine prevention in monoclonal antibody form?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which option describes CGRP antagonists used for migraine prevention in monoclonal antibody form?

Monoclonal antibodies targeting the CGRP pathway are used for migraine prevention. These are large protein biologics given by injection on a monthly or quarterly schedule, and they work by either sequestering CGRP itself or blocking its receptor, reducing CGRP signaling that contributes to migraine attacks. Because they are antibodies, they’re described as CGRP antagonists in monoclonal antibody form—the umabs. This differentiates them from small-molecule CGRP antagonists (gepants) like rimegepant and atogepant, which are not monoclonal antibodies. Traditional preventive options such as beta-blockers or anticonvulsants act through other mechanisms and do not directly target CGRP.

Monoclonal antibodies targeting the CGRP pathway are used for migraine prevention. These are large protein biologics given by injection on a monthly or quarterly schedule, and they work by either sequestering CGRP itself or blocking its receptor, reducing CGRP signaling that contributes to migraine attacks. Because they are antibodies, they’re described as CGRP antagonists in monoclonal antibody form—the umabs. This differentiates them from small-molecule CGRP antagonists (gepants) like rimegepant and atogepant, which are not monoclonal antibodies. Traditional preventive options such as beta-blockers or anticonvulsants act through other mechanisms and do not directly target CGRP.

More practice questions